All companies
BioLife Solutions logo

What smart money is saying about BioLife SolutionsUnited States flag

BLFS · Healthcare · Medical - Instruments & Supplies · Market cap $1.71B

1 fund in our archive has pitched BioLife Solutions — most recently Diamond Hill Small Cap Fund in June 2026.

Company profile

BioLife Solutions, Inc. (BLFS) operates as a global provider of specialized bioproduction tools and services, primarily catering to the cell and gene therapy industry. Its market reach extends across the United States, Canada, Europe, the Middle East, Africa, and other international regions. The company's offerings are essential for various stages of biologic-based therapy development, spanning from foundational and applied research to large-scale commercial manufacturing. Key products include proprietary biopreservation media, such as HypoThermosol FRS and CryoStor, which are engineered to minimize delayed cell damage and death typically associated with preservation. Complementing these are the ThawSTAR products, an automated line of devices for thawing vials and cryobags, designed to precisely manage the heat and timing for optimal biologic material thawing. BLFS also provides innovative cloud-connected evo shipping containers for the passive storage and secure transport of temperature-sensitive biologics and pharmaceuticals. Additionally, its comprehensive range encompasses liquid nitrogen laboratory freezers, various cryogenic equipment and accessories, and specialized storage services for biological and pharmaceutical products. Products are distributed both directly to customers and through a network of third-party distributors. Established in 1987, BioLife Solutions, Inc. maintains its headquarters in Bothell, Washington.

Get an email when a fund writes about it

Summarize with Warren AI
1
Reported positions
1
Bought
0
Sold
1
Letter

Position history

Every position in BioLife Solutions on record in the archive was reported in Q2 2026, across 1 fund letter1 opened or added to the position.

Fund letters reporting a position in BioLife Solutions, by quarter
QuarterLettersBoughtSoldTheses
Q2 20261101

Fund activity · 1 position · 1 move

  • June 2026
    • Cell and gene therapy products and services supplier BioLife Solutions provides essential materials used to manufacture, store and transport living human cells. The company’s biopreservation media are supported by FDA Master Files and embedded across approved therapies and clinical trials. We initiated a position as we believe the company enjoys a distinct advantage over other players in the space, as switching providers can be difficult due to validation requirements, regulatory filings and manufacturing processes.
    BioLife Solutions

Fund coverage · 1 thesis

Read every full thesis on BioLife Solutions

Unlock all 1 thesis — the full reasoning behind what funds are buying, plus unlimited access to the entire archive.

View plans
Share this ledger